• Info
  • Significant Ownership

Significant Ownership of Squadron Capital Management LLC

Signature - Title
/s/ Matthew Sesterhenn - Partner
Location
Hinsdale, IL
Summary
This page shows a list of all the recent SCHEDULE 13D/G filings made by Squadron Capital Management LLC.

Notify me when Squadron Capital Management LLC files a new Schedule 13D/G report.

⭐ Subscribe ⭐

Significant Ownership of Squadron Capital Management LLC

Sym Company Class Ownership Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
RLMD RELMADA THERAPEUTICS, INC. Common Stock ($.001 par value) 9.9% $1,980,090 +$749,475 3,298,500 +61% Squadron Capital Management LLC 30 Jun 2025
KTTA Pasithea Therapeutics Corp. Common Stock, par value $0.0001 per share 9.9% $1,577,051 2,252,930 Squadron Capital Management LLC 28 Nov 2025
LPCN Lipocine Inc. Common Stock, par value $0.0001 per share 9% $1,435,000 500,000 Squadron Capital Management LLC 18 Dec 2025
PALI PALISADE BIO, INC. Common Stock, par value $0.01 per share 8.5% $4,785,000 8,250,000 Squadron Capital Management LLC 01 Oct 2025
TRAW Traws Pharma, Inc. Common Stock, par value $.01 per share 8.4% $1,093,941 +$315,594 591,000 +41% Squadron Capital Management LLC 30 Sep 2025
SPRBD SPRUCE BIOSCIENCES, INC. Common Stock, par value $0.0001 per share 6.6% $640,500 70,000 Squadron Capital Management LLC 08 Oct 2025
NXTC NextCure, Inc. Common Stock, $0.001 par value per share 6.5% $1,017,087 173,861 Squadron Capital Management LLC 21 Oct 2025

Schedules 13D/G Reported by Squadron Capital Management LLC:

Sym Target Class Ownership Change Current Shares Change Value Reporting name Form Report Period Filing Date
* An asterisk sign (*) next to the price indicates that the price is likely invalid.